WeVote
Log In

Bill

Bill

S 8925

Prohibits the sale of 7-hydroxymitragynine products

2025 Regular Session Introduced by Jake Ashby and 6 co-sponsors

Prohibits sale of products with more than 2% 7-hydroxymitragynine or over 1 mg per serving in NY, with civil penalties up to $3,000/$6,500.

RETURNED TO SENATE
0
WeVote Research Nonpartisan
Bill Summary · S 8925

Summary of Bill S.8925 (2025-2026) – New York

Title

Prohibits the sale of 7-hydroxymitragynine products

Purpose and intent

  • Establishes a statewide prohibition on the sale, offer for sale, delivery, or distribution of products that contain 7-hydroxymitragynine above specified thresholds.
  • Aims to reduce availability of 7-hydroxymitragynine-containing goods in New York by imposing civil penalties on entities that violate the prohibition.
  • Proceeds from civil penalties would be deposited into the New York State Drug Treatment and Public Education Fund.

Key provisions

Definitions

  • 7-hydroxymitragynine products: Any substance, material, mixture, compound, preparation, extract, or finished goods that contains 7-hydroxymitragynine at:
    • more than 2% of total alkaloids, or
    • more than 1 milligram per serving.

Scope of application

  • Applies to the sale, offer for sale, delivery, or distribution of all 7-hydroxymitragynine products within New York State.
  • Prohibits knowingly selling, offering for sale, or delivering such products by any business entity operating in the state (including corporations, partnerships, LLCs, firms, online platforms, etc.).

Penalties

  • Civil penalties for violations:
    • First violation: up to $3,000.
    • Each subsequent violation: up to $6,500.
  • Penalties recoverable by the New York State Attorney General through civil action.
  • All collected penalties deposited into the New York State Drug Treatment and Public Education Fund (per the state finance law, §99-jj).

Effective date

  • The act would take effect 90 days after becoming law.

Entities potentially affected

  • Businesses operating in New York that sell or distribute products containing 7-hydroxymitragynine, including:
    • Corporations
    • Partnerships
    • Limited liability companies
    • Firms
    • Online platforms and marketplaces

Procedural/timeline aspects

  • Introduced January 16, 2026.
  • Referred to the Committee on Consumer Protection.
  • Effectiveness contingent on enactment and the 90-day post-enactment period.

Additional notes

  • The bill creates a new General Business Law § 392-l to regulate and enforce the prohibition.
  • Public health and consumer protection rationale centers on controlling substances with potential risk associated with 7-hydroxymitragynine.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.